Searle Daypro lack of platelet effect claim cited in FDA letter.
Executive Summary
SEARLE DAYPRO POSTER CLAIM ON LACK OF PLATELET EFFECT CITED BY FDA Division of Drug Marketing, Advertising & Communications in an April 10 letter to the company. "Specifically, DDMAC is concerned that Searle makes claims that `a new study shows no clinically significant impact on platelets' and `small effect on ex vivo stimulated platelet aggregation,'" the letter says.